Articles related to VISION LOSS

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.

In a recent study, color Doppler ultrasound identified Giant Cell Arteritis in 44% of suspected cases, proving its effectiveness as a first-line diagnostic tool. This method offers a significant advantage in managing patient care by potentially reducing the need for subsequent invasive testing.

A groundbreaking study in The Lancet Neurology reports that 94% of patients with posterior cortical atrophy also have Alzheimer’s disease pathology, stressing the need for heightened awareness among clinicians for earlier diagnosis and intervention.

The identification of subretinal drusenoid deposits (SDDs), which carry the highest risk for AMD progression, is a critical aspect of early diagnosis.

A new gene editing technique has been developed that can potentially help reverse vision loss. Researchers have used the technique, called ‘prime editing,’ to target and correct the genetic mutation that causes retinitis pigmentosa, a genetic eye disease that causes progressive vision loss and eventually blindness. The study was conducted on mice, and the technique was able to restore visual function in the mice, demonstrating the potential of prime editing as a treatment for retinitis pigmentosa. As an optometrist, it’s important to keep up-to-date with advancements in the field of gene editing and the potential implications for treating genetic eye diseases. This new prime editing technique, demonstrated to reverse vision loss in mice with retinitis pigmentosa, shows promise as a potential treatment for the disease in humans. As further research is conducted, it will be important for optometrists to stay informed about developments in this area and be prepared to discuss potential treatments with their patients.